Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
arumakimig
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Arumakimig (MAS825) is a dual-acting monoclonal antibody developed by Novartis that simultaneously targets and neutralizes interleukin-1 beta (IL-1β) and interleukin-18 (IL-18). By inhibiting these two key pro-inflammatory cytokines, arumakimig aims to suppress the systemic autoinflammatory signaling pathways that drive various diseases. It is currently under clinical investigation primarily for the treatment of VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) syndrome, a rare and severe autoinflammatory condition characterized by systemic inflammation and hematologic abnormalities. The drug has also been explored in other inflammatory contexts, including COVID-19-related pneumonia.
- Other names
- arumakimig
02
Targets
IL18 (Interleukin-18)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on arumakimig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on arumakimig.